Mayne Pharma Group (MYX) Stock Overview
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MYX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.66 |
| 52 Week High | AU$6.50 |
| 52 Week Low | AU$2.04 |
| Beta | 1.0 |
| 1 Month Change | -4.32% |
| 3 Month Change | -4.32% |
| 1 Year Change | -47.53% |
| 3 Year Change | -43.04% |
| 5 Year Change | -56.39% |
| Change since IPO | -77.83% |
Recent News & Updates
Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential
Catalysts About Mayne Pharma Group Mayne Pharma Group is a specialty pharmaceutical company focused on Women's Health, Dermatology and International markets. What are the underlying business or industry changes driving this perspective?
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
Catalysts About Mayne Pharma Group Mayne Pharma Group is a pharmaceutical company focused on Women's Health, Dermatology and International markets, with an emphasis on branded products and specialized distribution models. What are the underlying business or industry changes driving this perspective?
None
Analysts have reduced their price target for Mayne Pharma Group from A$5.75 to A$4.62, citing updated assumptions that pair a lower revenue growth outlook with a slightly higher discount rate. This is partly offset by a firmer profit margin and a lower future P/E multiple.Recent updates
Women’s Health Expansion And Manufacturing Upgrade Will Support Stronger Long-Term Earnings Potential
Catalysts About Mayne Pharma Group Mayne Pharma Group is a specialty pharmaceutical company focused on Women's Health, Dermatology and International markets. What are the underlying business or industry changes driving this perspective?Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
Catalysts About Mayne Pharma Group Mayne Pharma Group is a pharmaceutical company focused on Women's Health, Dermatology and International markets, with an emphasis on branded products and specialized distribution models. What are the underlying business or industry changes driving this perspective?None
Analysts have reduced their price target for Mayne Pharma Group from A$5.75 to A$4.62, citing updated assumptions that pair a lower revenue growth outlook with a slightly higher discount rate. This is partly offset by a firmer profit margin and a lower future P/E multiple.Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile
Catalysts About Mayne Pharma Group Mayne Pharma Group focuses on branded and specialty pharmaceutical products in Women's Health, Dermatology and International markets. What are the underlying business or industry changes driving this perspective?Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%
Mayne Pharma Group Limited ( ASX:MYX ) shareholders would be excited to see that the share price has had a great month...A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb
Mayne Pharma Group Limited ( ASX:MYX ) shares have had a really impressive month, gaining 30% after a shaky period...Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
The latest analyst coverage could presage a bad day for Mayne Pharma Group Limited ( ASX:MYX ), with the analysts...Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers
One thing we could say about the analysts on Mayne Pharma Group Limited ( ASX:MYX ) - they aren't optimistic, having...Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is Mayne Pharma Group (ASX:MYX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Market forces rained on the parade of Mayne Pharma Group Limited ( ASX:MYX ) shareholders today, when the analysts...We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
The results at Mayne Pharma Group Limited ( ASX:MYX ) have been quite disappointing recently and CEO Scott Richards...Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mayne Pharma Group...Shareholder Returns
| MYX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -1.8% | 4.6% | 2.0% |
| 1Y | -47.5% | -18.6% | 2.4% |
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -18.6% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 2.4% over the past year.
Price Volatility
| MYX volatility | |
|---|---|
| MYX Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: MYX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MYX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 491 | Aaron Gray | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers.
Mayne Pharma Group Limited Fundamentals Summary
| MYX fundamental statistics | |
|---|---|
| Market cap | AU$216.11m |
| Earnings (TTM) | -AU$82.20m |
| Revenue (TTM) | AU$407.11m |
Is MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYX income statement (TTM) | |
|---|---|
| Revenue | AU$407.11m |
| Cost of Revenue | AU$152.12m |
| Gross Profit | AU$254.99m |
| Other Expenses | AU$337.20m |
| Earnings | -AU$82.20m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 62.64% |
| Net Profit Margin | -20.19% |
| Debt/Equity Ratio | 10.5% |
How did MYX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/01 23:38 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mayne Pharma Group Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Dunlop | BofA Global Research |
| Madeleine Williams | Canaccord Genuity |
| John Deakin-Bell | Citigroup Inc |